Reid, D M <br/><br/>
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.  [electronic resource] 

 -  Calcified tissue international  Oct 2001 
 - 242-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0171-967X 
<br/><br/><label>Standard No.: </label>10.1007/s00223-001-1060-8  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Bone Density--drug effects<br/>Bone and Bones--drug effects<br/>Calcium Channel Blockers--therapeutic use<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Etidronic Acid--analogs & derivatives<br/>Humans<br/>Male<br/>Middle Aged<br/>Osteoporosis--chemically induced<br/>Prednisone--adverse effects<br/>Risedronic Acid<br/>Spinal Fractures--chemically induced<br/>Treatment Outcome